Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double-blind randomized trial with placebo control

(2019) Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double-blind randomized trial with placebo control. Psychiatry and Clinical Neurosciences.

Full text not available from this repository.

Official URL: https://www2.scopus.com/inward/record.uri?eid=2-s2...

Abstract

Aim: The role of the glutamatergic system in the pathogenesis of obsessive–compulsive disorder (OCD) has been shown by numerous studies. The aim of the present randomized, double-blind, placebo-controlled, 12-week trial was to assess the efficacy and tolerability of amantadine as an adjuvant to fluvoxamine in the treatment of patients with moderate to severe OCD. Methods: One hundred patients diagnosed with moderate to severe OCD were randomized into two parallel groups to receive fluvoxamine (100 mg twice a day) plus placebo or fluvoxamine (100 mg twice a day) plus amantadine (100 mg daily) for 12 weeks. All patients received 100 mg/day fluvoxamine for 28 days followed by 200 mg/day for the rest of the trial, regardless of their treatment groups. Patients were evaluated for response to treatment using the Yale–Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at Weeks 4, 10, and 12. The main outcome measure was to assess the efficacy of amantadine in improving the OCD symptoms. Results: Repeated-measure analysis of variance showed a significant effect for Time × Treatment interaction (Greenhouse–Geisser corrected: F = 3.84, d.f. = 1.50, P = 0.03) in the Y-BOCS total score and a significant effect for Time × Treatment interaction (Greenhouse–Geisser corrected: F = 5.67, d.f. = 1.48, P < 0.01) in the Y-BOCS Obsession subscale score between the two groups. Conclusion: The results of this study suggest that amantadine may be effective as an augmentative agent in the treatment of moderate-to-severe OCD. © 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology

Item Type: Article
Keywords: amantadine; fluvoxamine; amantadine; amino acid receptor blocking agent; fluvoxamine; serotonin uptake inhibitor, abdominal pain; adjuvant therapy; adult; Article; clinical effectiveness; constipation; controlled study; decreased appetite; disease severity; double blind procedure; drug efficacy; drug screening; drug tolerability; female; headache; human; increased appetite; insomnia; major clinical study; male; nervousness; obsessive compulsive disorder; outcome assessment; randomized controlled trial; side effect; treatment duration; treatment response; tremor; Yale Brown Obsessive Compulsive Scale; combination drug therapy; drug potentiation; middle aged; obsessive compulsive disorder; outcome assessment; severity of illness index; young adult, Adult; Amantadine; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment (Health Care); Serotonin Uptake Inhibitors; Severity of Illness Index; Young Adult
Page Range: pp. 169-174
Journal or Publication Title: Psychiatry and Clinical Neurosciences
Volume: 73
Number: 4
Identification Number: 10.1111/pcn.12803
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/1977

Actions (login required)

View Item View Item